Skip to main content
. 2020 Aug 17;12(8):2312. doi: 10.3390/cancers12082312

Figure 6.

Figure 6

PM01183 inhibits C26-induced splenomegaly. Splenomegaly was visually inspected (A, scale bar 0.5 cm) 28 days after tumor injection. Spleen weights from mice euthanized when showing signs of distress are shown (B). Arrows indicate the length of treatments. Plasma levels of IL-6 (C), M-CSF (D) and IL-1β (E) were measured using multiplex assays in PBS-mice (6/group), C26-mice treated with PM01183 (6/group) or vehicle (10/group) after 10–13 days from tumor injection. PBS-treated mice were used as controls. Results are plotted as mean ± SEM. Linear regression t-test. Intercepts: ** p ≤ 0.01 (C26-vehicle vs. C26-PM); slopes: †† p ≤ 0.01 (C26-vehicle vs. PBS), † p ≤ 0.05 (C26-PM vs. PBS) (B). * p ≤ 0.05, ** p ≤ 0.01, Kruskal‒Wallis with post-hoc Dunn’s multiple comparison test (C,D) or one-way ANOVA with post-hoc Tukey’s multiple comparison test (E).